Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H18ClNO2S |
| Molecular Weight | 335.848 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCOC1=CC(NC(=S)C2=C(C)OC=C2)=CC=C1Cl
InChI
InChIKey=YZHIXLCGPOTQNB-UHFFFAOYSA-N
InChI=1S/C17H18ClNO2S/c1-11(2)6-8-21-16-10-13(4-5-15(16)18)19-17(22)14-7-9-20-12(14)3/h4-7,9-10H,8H2,1-3H3,(H,19,22)
| Molecular Formula | C17H18ClNO2S |
| Molecular Weight | 335.848 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
N-(4-Chloro-3-((3-Methyl-2-Butenyl)Oxy)Phenyl)-2-Methyl-3-Furancarbothioamide (also known as UC-781) is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor patented by Uniroyal Chemical Company, Inc. for prevention of HIV transmission. UC-781 is a potent inhibitor of reverse transcriptase-dependent pyrophosphorolysis, and purportedly restores the chain-terminating activity of zidovudine (AZT) against AZT-resistant virus. In clinical trials single and 7-day topical rectal exposure of UC-781 was safe with no significant adverse events, no detected UC-781 plasma drug levels, no significant mucosal changes, and high participant acceptability. Ex vivo biopsy infections demonstrated marked suppression of HIV infectibility, identifying a potential early biomarker of efficacy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. | 2008-12 |
|
| Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. | 2007-05 |
|
| Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants. | 2007-04 |
|
| Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. | 2007-01 |
|
| In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. | 2006-05 |
|
| Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 2006-02 |
|
| Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. | 2005-05 |
|
| Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. | 2005-05 |
|
| The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. | 2005-04-25 |
|
| Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. | 2004-10 |
|
| In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. | 2004-10 |
|
| A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. | 2004-10 |
|
| In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. | 2004-01 |
|
| Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. | 2003-10 |
|
| Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. | 2003-09 |
|
| Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. | 2001-06-07 |
|
| Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. | 2000-05 |
|
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | 2000-04-10 |
|
| Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine. | 2000-02-15 |
|
| Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. | 1999-08 |
|
| Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. | 1998-10-13 |
|
| Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. | 1998-07-09 |
|
| A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. | 1998-06 |
|
| 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. | 1998-03 |
|
| A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. | 1998-02-10 |
|
| Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. | 1997-11 |
|
| Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. | 1997-06-10 |
|
| Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. | 1997-05-19 |
|
| Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. | 1997-04 |
|
| Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. | 1997-04 |
|
| Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. | 1996-08-14 |
|
| Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. | 1996-08 |
|
| Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. | 1996-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21969851
0.1%, 0.25%
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:48 GMT 2025
by
admin
on
Mon Mar 31 18:32:48 GMT 2025
|
| Record UNII |
L7K247H29H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C97453
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
675186
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
178870-32-1
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
L7K247H29H
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
DTXSID10170581
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
3000926
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
C78046
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY | |||
|
DB05871
Created by
admin on Mon Mar 31 18:32:48 GMT 2025 , Edited by admin on Mon Mar 31 18:32:48 GMT 2025
|
PRIMARY |